Patents by Inventor Michael Alpert

Michael Alpert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD4 MUTEINS AND METHODS OF USING THE SAME
    Publication number: 20250215063
    Abstract: The invention relates to proteins that contain the CD4 domain 1 and the CD4 domain 2 (CD4 D1D2), wherein the CD4 D1D2 contains one or more mutations compared to wild-type human CD4 D1D2, and to methods of using the proteins for treating a human immunodeficiency virus (HIV) infection in a subject.
    Type: Application
    Filed: February 12, 2025
    Publication date: July 3, 2025
    Inventors: Michael Farzan, Matthew Gardner, Ina Fetzer, Michael Alpert, Charles Bailey
  • CD4 muteins and methods of using the same
    Patent number: 12252527
    Abstract: The invention relates to proteins that contain the CD4 domain 1 and the CD4 domain 2 (CD4 D1D2), wherein the CD4 D1D2 contains one or more mutations compared to wild-type human CD4 D1D2, and to methods of using the proteins for treating a human immunodeficiency virus (HIV) infection in a subject.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: March 18, 2025
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, EMMUNE, INC.
    Inventors: Michael Farzan, Matthew Gardner, Ina Fetzer, Michael Alpert, Charles Bailey
  • SCAFFOLDED ANTIGENS AND ENGINEERED SARS-COV-2 RECEPTOR-BINDING DOMAIN (RBD) POLYPEPTIDES
    Publication number: 20230414748
    Abstract: The present invention provides scaffolded antigens that have demonstrated improved biochemical and immunogenic properties. The invention also provides engineered SARS-CoV-2 immunogens that contain a modified receptor-binding domain (RBD) sequence. Also provided in the invention are vaccine compositions that contain the scaffolded antigens, including the engineered RBD polypeptides that are fused to the scaffold proteins described herein. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating SARS-CoV-2 infections.
    Type: Application
    Filed: November 16, 2021
    Publication date: December 28, 2023
    Inventors: Michael Farzan, Brian Quinlan, Yan Guo, Huihui Mu, Wenhui He, Hyeryun Choe, Lizhou Zhang, Charles Bailey, Michael Alpert
  • CD4 MUTEINS AND METHODS OF USING THE SAME
    Publication number: 20230159616
    Abstract: The invention relates to proteins that contain the CD4 domain 1 and the CD4 domain 2 (CD4 D1D2), wherein the CD4 D1D2 contains one or more mutations compared to wild-type human CD4 D1D2, and to methods of using the proteins for treating a human immunodeficiency virus (HIV) infection in a subject.
    Type: Application
    Filed: March 21, 2019
    Publication date: May 25, 2023
    Inventors: Michael Farzan, Matthew Gardner, Ina Fetzer, Michael Alpert, Charles Bailey
  • Virtual Environment with Targeted Advertising and Rewards
    Publication number: 20130282454
    Abstract: A computer system and computer-implemented method present a suite of challenging and entertaining mobile games, obstacles, or tasks (“challenges”) within a navigable virtual environment simulating a real world venue. Businesses may reach consumers in a targeted, non-invasive, and integrated way with promotions, coupons, merchandise, affinity points or other prizes presented within the virtual environment. Certain advertising and promotions may be sent to particular users based upon user preferences, past user activity, user location, and/or other factors. The rewards (such as points or prizes) offered may also be targeted and selected based upon user preferences, past user activity, user location, and/or other factors. The rewards may be redeemable and transferrable.
    Type: Application
    Filed: April 19, 2013
    Publication date: October 24, 2013
    Applicant: Landslide IP Group, LLC
    Inventors: Michael Alpert, Marcelo Ballona